Physician profile
Sandy Chan
NPI 1205366267
$3,865.03
in general payments reported to CMS, 2019-2025
37 companies · $1,186 in 2025
The $1,186 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $745 · 2022: $418 · 2023: $506 · 2024: $1,010 · 2025: $1,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,701.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $542.70 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $391.80 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $380.89 | 2021-2025 | |
| Gilead Sciences, INC. | $315.35 | 2021-2025 | Livdelzi |
| Astrazeneca Pharmaceuticals Lp | $286.34 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $260.28 | 2021-2023 | Mounjaro |
| Amarin Pharma, INC. | $224.21 | 2021 | |
| Esperion Therapeutics, INC. | $168.47 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.79 | 2021-2024 | Cyltezo |
| Mallinckrodt Hospital Products INC. | $126.62 | 2024 | Terlivaz |
| Merck Sharp & Dohme LLC | $101.34 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Amgen INC. | $97.88 | 2024-2025 | Evenity, Repatha, Prolia |
| Horizon Therapeutics Plc | $65.59 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $65.41 | 2023-2025 | Rexulti |
| Pfizer INC. | $64.26 | 2022-2024 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.